Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II Sells 8,078 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CFO Charles N. York II sold 8,078 shares of Day One Biopharmaceuticals stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $17.85, for a total value of $144,192.30. Following the completion of the sale, the chief financial officer now directly owns 217,293 shares of the company’s stock, valued at $3,878,680.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $17.17 on Friday. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -7.21 and a beta of -1.44. The business has a 50-day moving average of $15.45 and a two-hundred day moving average of $14.02. Day One Biopharmaceuticals, Inc. has a 1 year low of $9.67 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.07). As a group, equities research analysts expect that Day One Biopharmaceuticals, Inc. will post -2.67 earnings per share for the current year.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Day One Biopharmaceuticals by 67.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 16,817 shares of the company’s stock valued at $278,000 after purchasing an additional 6,750 shares during the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Day One Biopharmaceuticals by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 59,289 shares of the company’s stock valued at $979,000 after purchasing an additional 1,445 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Day One Biopharmaceuticals by 89.0% in the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company’s stock valued at $999,000 after purchasing an additional 32,238 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Day One Biopharmaceuticals by 77.7% in the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company’s stock valued at $3,051,000 after purchasing an additional 91,393 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Day One Biopharmaceuticals by 28.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company’s stock valued at $30,935,000 after purchasing an additional 472,654 shares during the last quarter. 87.95% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Tuesday, February 27th. Piper Sandler reissued an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Wedbush reissued an “outperform” rating and set a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Wednesday, April 24th. Finally, JPMorgan Chase & Co. boosted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Monday, April 22nd. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.